Keith Flaherty
Overview
Explore the profile of Keith Flaherty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
6148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Menzies A, Long G, Kohn A, Tawbi H, Weber J, Flaherty K, et al.
Neurooncol Adv
. 2024 May;
6(1):vdae033.
PMID: 38725995
Background: POLARIS (phase 2 [ph2]; NCT03911869) evaluated encorafenib (BRAF inhibitor) in combination with binimetinib (MEK1/2 inhibitor) in BRAF/MEK inhibitor-naïve patients with V600-mutant melanoma with asymptomatic brain metastases. Methods: The safety...
2.
Unger J, Stires H, Levit L, Stewart M, McKelvey B, Canin B, et al.
JCO Oncol Pract
. 2023 Aug;
19(10):907-916.
PMID: 37643386
Purpose: The onset of the COVID-19 pandemic created major disruptions in the conduct of cancer clinical trials. In response, regulators and sponsors allowed modifications to traditional trial processes to enable...
3.
Silverstein A, Dudaev A, Studneva M, Aitken J, Blokh S, Miller A, et al.
Prog Mol Biol Transl Sci
. 2022 Aug;
190(1):219-276.
PMID: 36008000
Medical abzymology has made a great contribution to the development of general autoimmunity theory: it has put the autoantibodies (Ab) as the key brick of the theory to the level...
4.
Allen J, Kline C, Prabhu V, Wagner J, Ishizawa J, Madhukar N, et al.
Oncotarget
. 2021 Oct;
12(21):2231.
PMID: 34676056
[This corrects the article DOI: 10.18632/oncotarget.11814.].
5.
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, et al.
Clin Cancer Res
. 2021 Oct;
27(24):6800-6814.
PMID: 34593527
Purpose: To investigate the therapeutic role of a novel telomere-directed inhibitor, 6-thio-2'-deoxyguanosine (THIO) in gliomas both and . Experimental Design: A panel of human and mouse glioma cell lines was...
6.
Guhan S, Shaughnessy M, Rajadurai A, Taylor M, Kumar R, Ji Z, et al.
J Invest Dermatol
. 2021 Mar;
141(8):2018-2027.e4.
PMID: 33745909
Approximately half of melanoma tumors lack a druggable target and are unresponsive to current targeted therapeutics. One proposed approach for treating these therapeutically orphaned tumors is by targeting transcriptional dependencies...
7.
Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, et al.
J Immunother Cancer
. 2021 Feb;
9(2).
PMID: 33632901
Background: Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of...
8.
Chen A, Flaherty K, ODwyer P, Giantonio B, Marinucci D, Lee J, et al.
JCO Precis Oncol
. 2020 Nov;
4.
PMID: 33163848
Purpose: To identify factors that may influence physician participation in tumor profiling studies and to assess the routine use of tumor profiling in clinical practice. Methods: Physicians in the National...
9.
Ji Z, Njauw C, Guhan S, Kumar R, Reddy B, Rajadurai A, et al.
J Invest Dermatol
. 2020 Nov;
141(5):1317-1324.e1.
PMID: 33159968
Targeted BRAF(V600E) suppression by selective BRAF inhibitors (BRAFis; e.g., vemurafenib and dabrafenib) has led to a sea change in the treatment of metastatic melanoma. Despite frequent upfront responses, acquired resistance...
10.
Marusak C, Thakur V, Li Y, Freitas J, Zmina P, Thakur V, et al.
Clin Cancer Res
. 2020 Aug;
26(22):6039-6050.
PMID: 32820016
Purpose: The extracellular matrix (ECM) is an intriguing, yet understudied component of therapy resistance. Here, we investigated the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of...